In Brief: Icos/Glaxo Wellcome
Icos/Glaxo Wellcome: Dissolve 1991 collaboration on phosphodiesterase inhibitors. Icos will have rights to "PDE inhibitors arising from the collaboration" and will pay royalties to Glaxo Wellcome. Icos began Phase I studies of a PDE-V inhibitor in January 1996 for use in congestive heart failure, angina and male erectile dysfunction...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth